Anika Therapeutics, Inc., together with its subsidiaries, develops, manufactures, and commercializes therapeutic products for tissue protection, healing, and repair. Its products are based on hyaluronic acid (HA), a naturally occurring biocompatible polymer found in the body. The company’s products include ORTHOVISC, ORTHOVISC mini, and MONOVISC for the treatment of osteoarthritis of the knee and various other joints; Hyalograft C Autograft for cartilage regeneration; Hyalofast, a biodegradable support for human bone marrow mesenchymal stem cells; Hyalonect, a woven gauze used as a graft wrap; Hyaloss, HYAFF fibers used to mix blood/bone grafts to form a paste for bone regeneration; and Hyaloglide, an ACP gel used in tenolysis treatment. It also provides wound care products that comprise Hyalograft 3D and Laserskin for the regeneration of skin; and Hyalomatrix for the treatment of burns and ulcers, as well as ELEVESS for facial wrinkles and scar remediation. In addition, the company offers AMVISC, AMVISC Plus, STAARVISC-II, Optivisc, AnikaVisc, and AnikaVisc Plus, which are injectable HA products used as viscoelastic agents in ophthalmic surgical procedures, such as cataract extraction and intraocular lens implantation. Further, it provides INCERT, a HA product for the prevention of post-surgical adhesions; Hyalobarrier, a post operative adhesion barrier for use in the abdomino-pelvic area; and Merogel, a woven fleece nasal packing, as well as Merogel Injectable, a hydrogel for the treatment of ear, nose, and throat disorders. Additionally, the company offers HYVISC, an injectable HA product used for the treatment of joint dysfunction in horses due to non-infectious synovitis associated with equine osteoarthritis. Anika Therapeutics, Inc. markets its products directly, as well as through a network of distributors worldwide. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.